Kolling Institute researchers will help drive an exciting international project to identify the genetic links to Parkinson’s disease and new ways to treat the debilitating disorder.
The program will bring together leading researchers from Sweden, the United States and Australia after a $12.5 million grant from the Aligning Science Across Parkinson’s initiative, which will be administered by the Michael J. Fox Foundation for Parkinson’s Research.
The Kolling Institute’s Executive Director Professor Carolyn Sue is thrilled to be involved, with the degenerative movement disorder impacting more than six million people worldwide.
“Parkinson’s disease is one of the biggest neurological health challenges this century, affecting an increasing number of people due to our ageing population,” she said.
Professor Sue, who is also the Director of Neurogenetics at Royal North Shore Hospital, said the project will use state-of-art technologies and a very specialised approach involving gene editing.
“Our research will investigate three specific genes linked to the disease, including the LRRK2, PARKIN and A-SYNUCLEIN genes,” she said.
“By understanding how genes contribute to Parkinson’s disease, we will be in a better position to identify new therapies that could slow the disease process.